This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neubauer, B. L. Articles by Graff, J. R. Search for Related Content PubMed PubMed Citation Articles by Neubauer, B. L. Articles by Graff, J. R.

The Selective Estrogen Receptor Modulator Trioxifene (LY133314) Inhibits Metastasis and Extends Survival in the PAIII Rat Prostatic Carcinoma Model

Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285

Trioxifene (LY133314) is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor (ER) and antagonistic activity against ER-mediated gene expression. The PAIII rat prostatic adenocarcinoma (PCa) is an androgen receptor-negative, ER- and ERß-positive, spontaneously metastatic rodent tumor cell line. After s.c. implantation of 10⁶ PAIII cells in the tail, s.c. administration of trioxifene (2.0, 4.0, 20.0, or 40.0 mg/kg-day) for 30 days produced significant (P < 0.05) inhibition of PAIII metastasis from the primary tumor in the tail to the gluteal and iliac lymph nodes (maximum nodal weight decreases, 86% and 88% from control values, respectively). PAIII metastasis to the lungs was significantly inhibited by trioxifene treatment. Numbers of pulmonary foci in PAIII-bearing rats were significantly (P < 0.05) reduced by trioxifene administration in a dose-related manner (maximal reduction, 98% from control values). Continual administration of the compound significantly (P < 0.05) extended survival of PAIII-bearing rats. Trioxifene inhibited the proliferation of PAIII cells at micromolar levels in vitro but did not slow growth of the primary tumor growth in the tail. Trioxifene administration also produced regression of male accessory sex organs. In PAIII-tumor-bearing animals, trioxifene administration produced a maximal regression of 76% for ventral prostate and 64% for seminal vesicle (P < 0.05 for both). SERMs may be preferable to estrogens given their efficacy in experimental PCa models and relative lack of side effects observed in clinical trials. Our data support the contention that trioxifene represents a SERM with potential antimetastatic efficacy for the treatment of androgen-independent, metastatic PCa.

This article has been cited by other articles:

				O. Wada-Hiraike, O. Imamov, H. Hiraike, K. Hultenby, T. Schwend, Y. Omoto, M. Warner, and J.-A. Gustafsson Role of estrogen receptor beta in colonic epithelium PNAS, February 21, 2006; 103(8): 2959 - 2964. [Abstract] [Full Text] [PDF]

				M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]

				O. Imamov, G.-J. Shim, M. Warner, and J.-A. Gustafsson Estrogen Receptor beta in Health and Disease Biol Reprod, November 1, 2005; 73(5): 866 - 871. [Abstract] [Full Text] [PDF]

				M. Pollard and M. A. Suckow Hormone-Refractory Prostate Cancer in the Lobund-Wistar Rat Experimental Biology and Medicine, September 1, 2005; 230(8): 520 - 526. [Abstract] [Full Text] [PDF]

				V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, A. Maggi, P. G.V. Martini, B. S. Katzenellenbogen, L. Martini, M. Motta, et al. The Androgen Derivative 5{alpha}-Androstane-3{beta},17{beta}-Diol Inhibits Prostate Cancer Cell Migration Through Activation of the Estrogen Receptor {beta} Subtype Cancer Res., June 15, 2005; 65(12): 5445 - 5453. [Abstract] [Full Text] [PDF]

				K. F. Koehler, L. A. Helguero, L.-A. Haldosen, M. Warner, and J.-A. Gustafsson Reflections on the Discovery and Significance of Estrogen Receptor {beta} Endocr. Rev., May 1, 2005; 26(3): 465 - 478. [Abstract] [Full Text] [PDF]

				C. P. Cheung, S. Yu, K. B. Wong, L. W. Chan, F. M. M. Lai, X. Wang, M. Suetsugi, S. Chen, and F. L. Chan Expression and Functional Study of Estrogen Receptor-Related Receptors in Human Prostatic Cells and Tissues J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1830 - 1844. [Abstract] [Full Text] [PDF]

				X. Zhu, I. Leav, Y.-k. Leung, M. Wu, Q. Liu, Y. Gao, J. E. McNeal, and S.-M. Ho Dynamic Regulation of Estrogen Receptor-{beta} Expression by DNA Methylation During Prostate Cancer Development and Metastasis Am. J. Pathol., June 1, 2004; 164(6): 2003 - 2012. [Abstract] [Full Text] [PDF]